Search Results

The Neuroendocrine Cancer Foundation (formerly LACNETS) attended the 2025 Annual European Neuroendocrine Tumor Society (ENETS) Conference, a 3-day medical and scientific meeting of presentations on ground-breaking research and late-breaking study results, in Krakow, Poland. We learned from experts from around the world and collaborated with global partners.  While many of the sessions focus on medical and scientific data, the value of patient advocates was highlighted during the interactive INCA/ENETS joint session where the topic was on collaboration of NET researchers and patient advocates to improve neuroendocrine cancer research. While the Neuroendocrine Cancer Foundation was not a presenter during this session, we were mentioned by presenters as some of the examples of meaningful involvement in research. The key takeaway was that clinical research should involve patient advocacy organizations early and throughout the clinical trial process. To this aim, we strive to forge and deepen relationships to further research collaborations globally so that we can ultimately improve the lives of patients. Watch our interviews from the ENETS Symposium with NANETS President Emeritus Dr. Thor Halfdanarson and Ohio State University Comprehensive Cancer Center (OSUCCC)’s Medical Oncologist Dr. Vineeth Sukrithan.  NANETS President Emeritus Dr. Thor Halfdanarson discusses the positive news and  results from ITM’s phase 3 COMPETE trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus).  Click here to learn about COMPOSE, another ITM ongoing trial, for Well-differentiated, G2 and G3 GEP-NETs comparing PRRT versus CAPTEM (Capecitabine and Temozolomide), Everolimus or FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)>>> OSUCCC’s Medical Oncologist Dr. Vineeth Sukrithan discusses his takeaways from the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland.  THANKS TO OUR SPONSORS

On Saturday, March 29th, 2025, the Neuroendocrine Cancer Foundation held a Regional Neuroendocrine Patient Educational Event in Tucson, Arizona. Seventy-five members of the Neuroendocrine Cancer community, including patients, caregivers, expert speakers and advocacy representatives, gathered for an afternoon dedicated to learning, connection and hope. The event featured an inspiring story from someone living with Neuroendocrine Tumors (NET) and seven educational presentations covering key topics, including surgery, liver-directed therapy, systemic therapy, PRRT, nursing perspectives, and clinical trials. These sessions were followed by a 50-minute Q&A with a distinguished panel of NET experts, allowing attendees to ask questions and gain valuable insights. Beyond the presentations, the event provided an incredible opportunity for NET patients and caregivers to connect with others who truly understand their journey. We heard from many who felt inspired, empowered, and in great company.   The event highlighted the importance of community, knowledge, and the collective efforts of those dedicated to improving neuroendocrine cancer care and outcomes.  A special thank you to NANETS, who held their Regional Educational Event, for inviting us to share their conference space and expert speakers. They presented comprehensive information about neuroendocrine cancer to medical professionals. Be sure to share NANETS.net  with your doctors so they have an opportunity to learn more about the intricacies of NET.    The message of the day was clear: that we continue to move forward with hope, knowing that many brilliant minds are working diligently and collaboratively for those affected by Neuroendocrine Cancer.  A special thanks to our host and co-moderator, Dr. Junaid Arshad, and the UACC Team. Also, thanks to Dr. Aman Chauhan and Dr. Jaydira Del Rivero, who joined the Q&A panel. We are grateful for our 8 wonderful speakers: Kimberly, NET patient Bassam Sonbol, MD, Medical Oncologist; Mayo Clinic Phoenix Gagandeep Singh, MD, Surgical Oncologist; City of Hope Phoenix Gregory Woodhead, MD, PhD, Interventional Radiologist, University of Arizona Cancer Center Heloisa Soares, MD, PhD, Medical Oncologist; Huntsman Cancer Institute Holly Thompson, MD, MPH, Nuclear Medicine; University of Arizona Cancer Center  Linda Moe, RN, University of Arizona Cancer Center Pamela Kunz, MD, Medical Oncologist; Yale Cancer Center And two additional guest panelists: Aman Chauhan, MD, Medical Oncologist, Sylvester Cancer Center, University of Miami Jaydira Del Rivero, MD, Medical Oncologist and Endocrinologist, National Cancer Institute, National Institute of Health The slides from the speaker presentation can be viewed here: NETs 101: NET Terms & Concepts You Need to Know - Dr. Bassam Sonbol Surgery for NETs: To Cut or Not to Cut? - Dr. Gagandeep Singh Liver-Directed Therapy: Killing Liver Tumors without a Big Scar - Dr. Gregory Woodhead Systemic Therapy for NETs: Treatment Options for Metastatic Tumors - Dr. Heloisa Soares PRRT: Current & New Trends - Dr. Holly Thompson Nursing Perspective on the Management of NETs - Linda Moe, RN Clinical Trials: The Latest & Greatest - Dr. Pamela Kunz Here are additional resources mentioned during the event: LACNETS 2024 Educational Event with Dr. Gagandeep Singh on the “Evolving Management of NET Liver Metastases NCF Surgery Resources NCF Liver-Directed Therapy Resources NCF Clinical Trials Guide including the Ancora.ai neuroendocrine tumor clinical trial finder   Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs), Including Adrenocortical Carcinoma (ACC) To find out more about upcoming in-person and virtual Neuroendocrine Cancer Foundation events, visit our Upcoming Events & Meetings page . THANKS TO OUR SPONSORS

I remember quite vividly how overwhelmed I felt when my husband was abruptly and traumatically diagnosed with neuroendocrine tumor. Not only were we dealing with the emotional impact of the news, we were overwhelmed with the amount of information we needed to learn about this rare disease. Navigating the NET journey involves much learning as well as seeking the opinion of NET experts. Dr. Dan Li, Giovanna Imbesi, & Lisa Yen at the 2019 NANETS Symposium In February 2018, Giovanna and I had the opportunity to work with many NET experts as part of the Healing NET Summit . One of the main topics was patient-provider communication. It was from those discussions that Giovanna and I first asked the question, “What can we do to become better patients?” As we brainstormed with Dr. Dan Li , the concept of a “NET VITALS” worksheet was born. We imagined that patients could fill out a worksheet with the most important (aka“vital”) information that a NET expert would need to know about their disease. This worksheet would then serve two purposes: The patient would become more familiar with their own disease through the process of filling out the worksheet. The NET expert would have a concise document with the most important information about the person’s disease (i.e. “vitals” as in “vital signs”). The hope was that this would minimize issues with patients coming to see the experts with incomplete information as well as increase the patient’s knowledge and confidence before the appointment. The result would be a more efficient appointment with the NET expert with more time spent discussing the treatment plan. While this document may feel daunting, the intent is not for it to be filled out easily nor all at one time. Take a few breaths. Break it into chunks. Do a bit at a time. It is understandable that through the process of filling it out, you will have to go and dig through your records. You will discover words that you may not know and need to look them up through the resource links. You will leave some areas blank to discuss further with your doctor. In April 2018, LACNETS first introduced the NET VITALS tool in a LACNETS workshop. Its first official use was the LACNETS Annual Patient Education Conference on May 19, 2018. It continues to be a work in progress. Our hope is to help both patient and providers with this tool that will empower patients and improve patient-provider communication. BENEFITS OF FILLING OUT NET VITALS: Helps you prepare for your NET specialist appointment. Helps you understand your disease and how this information relates to you. Helps you get organized by compiling the information and records for your upcoming appointment with your NET specialist. Clarifies questions you have for your doctor(s). Helps make your upcoming appointment more efficient. Written by Lisa Yen, NP, NBC-HWC Director of Programs & Outreach, LACNETS

Upcoming Events & Meetings "Evolving Management of Carcinoid Heart Disease: What We Know & What's New" April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. Register NCF Regional NET Patient Educational Event May 17, 2025 The Neuroendocrine Cancer Foundation is hosting an in-person Neuroendocrine Cancer Educational Event for patients and caregivers in Santa Monica, California on Saturday, May 17th, from 3:45 -7:30 PM. Register 2025 NCF Neuroendocrine Cancer Patient Conference June 14, 2025 Registration to Open Soon NCF Regional NET Patient Educational Event Nov 8, 2025 Registration to Open Soon Virtual NET Patient & Caregiver Support Group (Weekly) Wednesday, Apr. 16, 23, 30. May 7, 14, 21, 28, 2025 NOON - 1:30 PM Pacific Join NCF via ZOOM Weekly on Wednesdays from 12 - 1:30 PM Pacific Time. We provide a collective, empathetic space for information & experience sharing, support & community. For NET Patients & Caregivers REGISTER Virtual NET Caregiver Support Group (Monthly on a Saturday) Next meeting Apr. 26, 8:00 - 10:00 AM Pacific We provide a safe space where NET caregivers can come together virtually for support and community. We encourage you to express your experiences, thoughts, and concerns amongst fellow caregivers. For NET caregivers only REGISTER Click here for recent events

< Back to the upcoming events page WATCH THE RECORDING Celebrate NET Cancer Day at the LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 3:30 pm. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Show how you live well with Neuroendocrine Cancer in our "Show & Tell" Video Slideshow (will be played during our reception). Post-Event Ice Cream Social There is no cost to attend. This event is made possible by the generosity of donors and sponsors. This event will not be broadcast. LOCATION Santa Monica Bay Woman's Club 1210 4th St, Santa Monica, CA 90401 Parking will be fully validated at SP+ Parking Garage Structure 1 at 1234 4th St, Santa Monica, CA. AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome LACNETS Team 9:10 - 9:20 AM A NET Impact Story A NET Patient 9:20 - 9:35 AM A NET Surgeon's Perspective on What to Ask Your Surgeon & How to Prepare for Surgery Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai 9:35 - 9:50 AM Alpha vs Beta PRRT: Which is for me? Martin Auerbach, MD, Nuclear Medicine, UCLA 9:50 - 10:20 AM Q&A Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai & Martin Auerbach, MD, Nuclear Medicine, UCLA 10:20 - 10:50 AM Break 10:50 - 10:55 AM A NET Impact Story A NET Caregiver 10:55 - 11:15 AM The Latest in NET Medical Therapies Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai 11:15 - 11:35 AM The Endocrine in Neuroendocrine Run Yu, MD, Endocrinologist, UCLA 11:35 - 11:50 AM Liver Directed Therapy for Neuroendocrine Liver Tumors H. Gabriel Lipshutz MD, Interventional Radiologist, Cedars-Sinai 11:50 AM - 12:30 PM Q&A All Faculty (Moderated by Lisa Yen) 12:30 - 1:30 PM Lunch & Networking 1:30 - 2:05 PM The Future of NETs: Evolving Treatments & Clinical Trials Jaydira Del Rivero, MD, Medical Oncologist, Endocrinologist, National Cancer Institute, National Institutes of Health 2:05 - 2:25 PM Spreading Awareness Globally: INCA's Think NENs Stephanie Alband, INCA President & PPA Executive Director 2:25 - 2:35 PM Let's Talk About NETs: How YOU Can Spread Awareness Heather Davis, LACNETS Associate Director of Advocacy & Outreach 2:35 - 3:00 PM Music Heals Drum Healing with John Fitzgerald 3:05 - 3:15 PM Closing LACNETS Team 3:15 - 4:30 PM Networking Reception with Show & Tell Slideshow MODERATORS : Andrew Hendifar, MD, & Lisa Yen, Director of Programs and Outreach SPEAKERS: ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. RUN YU, MD, PhD Endocrinologist, UCLA Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. H. GABRIEL LIPSHUTZ, MD Interventional Radiologist Cedars-Sinai Medical Center H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. JAYDIRA DEL RIVERO, MD Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. STEPHANIE ALBAND, MSBA Board President, INCA Executive Director, The Pheo Para Alliance Stephanie Alband, MSBA, joined Pheo Para Alliance in March of 2019. She has over 20 years of experience in the nonprofit industry, with ten years working exclusively for rare disease organizations, including the Huntington’s Disease Society of America and Angioma Alliance. Her experience with her daughter’s rare cancer has helped her better understand and successfully navigate the unique challenges faced by the rare disease community. She currently serves as the President for the International Neuroendocrine Cancer Alliance (INCA) and previously served as Communications Chair and a Member of the Board of Directors. JOHN FITZGERALD Drum Circle Facilitator & Coach Rhythm With a Purpose Before he fell in love with the transformational impact of coaching, and rhythm facilitation, John spent decades as a degreed percussionist performing jazz and classical music, and the amazing music of cultures from around the world. Rhythms, cycles, and improvisation have always been central to his joy and passion, the spontaneous personal expression that is such a vital part of all living cultures, and indeed, all our lives. As the Manager of Recreational Music Activities for Remo Inc., for 23 years, he created relationships with organizations and individuals, educating and advocating for the use of music for wellbeing in every imaginable population through a global network of partnerships, facilitators, and Remo’s distributor network. Presentations, training, and facilitated experiential activities at conferences and symposia were a central part of his work at Remo, and his passion as well. In addition to one on one work with individuals and organizational leaders, John designed and facilitated team-building, communication and leadership workshops for over 20 years. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Aman Chauhan’s presentation “NETS 101: Overview of NET Terms & Concepts " or Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis.” The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS REGISTER

The Neuroendocrine Cancer Foundation serves the neuroendocrine cancer (or NET) community by connecting patients, caregivers, and medical professionals. Find educational resources and connect with other NET patients and caregivers. READ MORE Clinical Trials Blog Resources by Topic Podcast UPCOMING EVENTS Apr 29, 2025 Register May 17, 2025 Register Visit our events page for more information >>> Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate Sign up for email Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE ABOUT THE NEUROENDOCRINE CANCER FOUNDATION The Neuroendocrine Cancer Foundation provides a community of support and education for neuroendocrine tumor (or neuroendocrine cancer or NET) patients and caregivers. Learn Our educational programs, including webinars , patient education conferences , a video library , podcast , and blog , provide information on diagnosis, treatment options, research and resources. We develop patient-friendly educational content that brings the latest medical information and research studies to NET patients and caregivers. Advocate We advocate f or all people impacted by this rare disease to improve health outcomes through early diagnosis. We raise awareness about neuroendocrine and carcinoid cancers among healthcare professionals and the public. Connect Our inclusive global community includes NET patients, family members, and caregivers. The Neuroendocrine Cancer Foundation makes it possible for patients to share experiences, encouragement, and hope through support groups , Health Coaching , and NETCONNECT , a buddy program connecting a newly-diagnosed NET patient with a long-time patient. Seven Facts About NET Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. NET is a rare cancer. In the United States, 7 in 100,000 people are diagnosed per year. NET can affect neuroendocrine cells throughout the body. NET is a difficult cancer to diagnose. Some (but not all) NET patients have symptoms from their cancer. The cause of NET is unknown. Seeking the opinion of a NET specialist is important for all NET patients. LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Play Video Play Video 04:05 Dr. Soulen Talks About 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr Michael Soulen, Interventional Radiologist at Penn. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 02:14 Dr. Kunz Shares 2023 Highlights and Her Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS Past President, Dr. Pamela Kunz. She talks about the highlights of 2023 and shares her hopes for 2024. Play Video Play Video 04:01 Dr. Strosberg Shares 2023 Highlights and Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr. Jonathan Strosberg, Medical Oncologist at Moffitt. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 03:40 Dr. Halfdanarson Shares 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS President Dr. Thor Halfdanarson. He talks about the highlights of 2023 and shares his hopes for 2024. Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide LATEST FROM NCF WATCH 400+ Videos on Various Topics 2024 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn About Active Clinical Trials RECENT EDUCATIONAL EVENTS Play Video Play Video 01:26:11 "Palliative Care for Neuroendocrine Cancer" Dr. Chandana Banerjee • 2024 #LACNETS Educational Event Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, a palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Visit LACNETS.org for more information. Play Video Play Video 01:35:06 "Evolving Management of NET Liver Metastases" Dr. Gagandeep Singh • 2024 #LACNETS Educational Event Join us to hear renowned liver and pancreas surgeon Dr. Gagandeep “Gaugs” Singh discuss the evolving algorithms in the management of NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. For more information, visit LACNETS.org. Play Video Play Video 01:27:16 "2024 Updates on Clinical Trials in Neuroendocrine Tumors" • 2024 LACNETS Event • April 25, 2024 Join us to learn about the latest in clinical trials for neuroendocrine tumors with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. For more information about Clinical Trials, visit https://www.lacnets.org/clinical-trials. For more information, visit LACNETS.org. Play Video Play Video 01:18:47 "TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors" • 2024 LACNETS Event • March 29, 2024 Learn about Tyrosine Kinase Inhibitors (TKIs), what they are and how they work with NET expert Dr. Jennifer Chan. Dr. Chan is the Vice President of the North American Neuroendocrine Tumor Society (NANETS) and the principal investigator of the CABINET trial. Hear the positive findings from that TKI study using Cabozantinib. She will discuss the latest in TKI treatments and how they may be a possible treatment option for many NET patients. For more information, visit lacnets.org. Play Video Play Video 01:29:36 "Carcinoid Heart Disease" • 2024 LACNETS Event • Feb 14, 2024 Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. Visit LACNETS.org for more information. Play Video Play Video 01:12:47 "PRRT: What We Know, Special Considerations & Clinical Trials" with Dr. Strosberg • Jan 11, 2024 Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. Visit LACNETS.org for more information. Play Video Play Video 01:19:50 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" • Dr. Yilun Koethe • Dec 9, 2023 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe, Interventional Radiologist, TRG Imaging. Learn more about minimally invasive liver directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo and radioembolization. ~ Visit LACNETS.org for more information. Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. LATEST PODCAST EPISODES RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine tumor (NET) experts answer the top 10 FAQs on various NET topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT Program A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient